key: cord-0857003-ox5dgh1p
authors: Schmedes, S. E.; Azarian, T.; Cella, E.; Motes, J.; Tekin, O.; Weiss, J.; Miller, N.; Blanton, J.
title: Introduction and community transmission of SARS-CoV-2 lineage A.2.5 in Florida with novel spike INDELS
date: 2021-12-05
journal: nan
DOI: 10.1101/2021.12.03.21266538
sha: 55f7aaa3570eb332600e17e78daedd1c388b38e6
doc_id: 857003
cord_uid: ox5dgh1p

SARS-CoV-2 (SC2) variants of concern (VOC) continue to emerge and spread globally, threatening the use of monoclonal antibody therapies and vaccine effectiveness. Several mutations in the SC2 spike glycoprotein have been associated with reduction in antibody neutralization. Genomic surveillance of SC2 variants has been imperative to inform the public health response regarding the use of clinical therapies in specific jurisdictions based on the proportion of particular variants (e.g., Gamma (P.1)) in a region. Florida Department of Health Bureau of Public Health Laboratories (BPHL) performs tiled-amplicon whole genome sequencing for baseline and targeted surveillance of SC2 isolates in Florida from clinical specimens collected from county health departments and hospitals throughout the state. Here, we describe the introduction of SC2 lineage A.2.5 in Florida, which contains S:L452R (a substitution of therapeutic concern) and two novel Spike INDELS, the deletion of 141-143 and ins215AGY, with unknown implications on immune response. The A.2.5 lineage was first detected in Florida among an outbreak at a healthcare facility in January 2021, and subsequent A.2.5 isolates were detected across all geographical regions throughout the state. A time-scaled maximum clade credibility phylogeny determined there were at least eight separate introductions of A.2.5 in the state. The time of introduction of a monophyletic Florida clade was established to be December 2020. The Spike INDELS were determined to reside in the N-terminal domain, a region associated with antibody neutralization. As community transmission of SARS-CoV-2 in Florida continues, genomic surveillance of circulating variants in Florida and the detection of emerging variants are critical for informing public health response to COVID-19.

SARS-CoV-2 (SC2) variants of concern continue to emerge and spread globally, highlighting the demand for increased SC2 surveillance at the local, national, and international level. Tiled-amplicon whole-genome sequencing (WGS) or targeted enrichment WGS has been the gold standard for SC2 surveillance to identify and track lineages which contain amino acid substitutions and/or insertions/deletions (INDELS) within the spike glycoprotein, which binds to the ACE-2 receptor during infection. Several spike glycoprotein mutations in VOCs have shown to have significant public health impacts such as increased transmission (1) (2) (3) (4) and may pose a threat to front-line therapeutics and vaccines (4) (5) (6) (7) (8) (9) . Active SC2 surveillance by WGS is imperative to detect novel spike mutations as soon as they emerge.

The Centers for Disease Control and Prevention (CDC) published a United States (U.S.) government interagency variant classification list characterizing variants in the United States with defined attributes: variant of interest (VOI), variant of concern (VOC), and variant of high consequence (VOHC) (10) . As of June 4, 2021, VOCs and VOIs comprised the majority of all lineages in the U.S. Among U.S. jurisdictions, Florida had one of the highest burdens of VOCs (> 80%) amid lineages circulating within the state (11).

Florida Department of Health (FDOH) Bureau of Public Health Laboratories (BPHL) has sequenced COVID-19-positive samples collected from patients throughout the state, as early as March 4, 2020. BPHL actively surveils lineages of public health interest in Florida, including variant classifications designated by CDC, WHO, and other international organizations (10, 12, 13) , and actively monitors changes in lineage frequencies in the state in addition to the emergence of novel spike mutations which may warrant further investigation.

In January 2021, BPHL detected the first cases of then SC2 lineage A.2.4 among an outbreak at a south Florida healthcare facility. Shortly after this first detection, additional A.2.4 cases were detected in routine surveillance samples collected from patients geographically dispersed across the state. The A.2.4

On March 29, 2021, the global A.2.5 lineage comprised 220 isolates with complete genomes from 13 countries ( Figure 1A ). The earliest collected A.2.5 clinical isolate submitted to GISAID was collected in Ecuador on December 1, 2020. Thirty-three A.2.5 isolates were from Florida, and the first clinical specimen in Florida was collected on January 16, 2021 

A maximum likelihood phylogeny demonstrated that lineage A.2.5 is globally distributed, with dominant clades found in Central and South America as well as the United States and Italy ( Figure 1B ). The phylogeny also resolved a clade of 17 Florida isolates. The remaining isolates from Florida were interspersed throughout the phylogeny suggesting multiple importations of this emerging lineage. To further investigate the emergence of lineage A.2.5, we performed a coalescent analysis. The maximum likelihood phylogeny ( Figure 1B ) was transformed into a time-scaled tree. It was then determined that sequence hCoV-19/Ecuador/USFQ-556/2020 was an outlier and was removed from the analysis. Assessment of temporal signal (i.e., molecular clock) indicated that the SARS-CoV-2 A.2.5 sequences evolved in a sufficient clock-like manner (r=0.26) (Figure 2A-B) . Time-scaled analysis estimated the SARS-CoV-2 lineage A.2.5 evolutionary rate as 5.15E-4 substitutions/site/year (95% HPD, 4.07E-4 -6.23E-4), consistent with the previous estimates (30).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021.

For SARS-CoV-2, a temporal signal with correlation coefficient > 0.2 is generally accepted as sufficient temporal signal for coalescent analysis. The root-to-tip genetic distance is regressed on the collection date. Points are colored by U.S. or non-U.S. (A) or by country (B). Regression lines are shown with upper and lower error intervals (shaded grey area) representing 90% confidence intervals.

The most recent common ancestor (TMRCA) of the root ranged between late December 2019 and February 2020 (mean January 2020) ( Figure 3 ). Strains from Luxembourg and one from the United States are located at the base of the main clade suggesting two independent and contemporaneous emergences of this lineage originated in the second half of 2020, when this lineage was first observed. The monophyletic clade comprising Florida strains originated in November 29, 2020 (95% HPD, October 24, 2020 -December 30, 2020); however, this early date was driven by two basal strains that may in fact represent a separate Florida introduction. Excluding those strains, the TMRCA of the clade is December 12, 2020 (95% HPD, November 27, 2020 -January 11, 2021). In addition to the dominant clade containing 17 strains, Florida isolates are interspersed throughout the maximum clade credibility (MCC) tree suggesting at least 8 separate introductions to the state (Figure 3 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021. ; 

The primary Florida clade all possessed Spike L141del, G142del, V143del, D215A, ins215AGY, L452R, and D614G, although 3/17 isolates had missing and low coverage at Spike 215. The deletions of Spike 141-143 and the insertion at 215 were most notable; therefore, we further explored the location of these INDELs by modeling their location on the three-dimensional structure of the spike glycoprotein. This modeling revealed that the INDELs both occurred in the N-terminal domain (NTD) (Figure 4 ). 

Since late 2020, SARS-CoV-2 variants continue to cause concern in the United States and globally. Spike protein mutations of therapeutic concern continue to emerge independently in lineages not classified as VOI or VOC (10), thus emphasizing the importance of SC2 genomic surveillance to detect novel substitutions of therapeutic concern (SOTC) as they emerge. Here, we described the introduction and transmission of lineage A.2.5 in Florida, which was introduced into the state near the end of 2020 around the same time as other VOCs first emerged in the U.S.

The A.2.5 lineage first emerged in Central America and the U.S. (15) , and molecular clock analysis estimates the emergence of TMRCA of the root of the lineage at the beginning of the pandemic, late December 2019 -February 2020, with an introduction into Florida a year later around December 2020 ( Figure 3 ). Lineage A.2.5 subsequently expanded rapidly to other regions around the world. In January 2020, A.2.5 specimens associated with an outbreak among patients and staff at a healthcare facility in Florida were detected, and subsequently after, sequenced A.2.5 specimens collected across the state from separate geographical locations, suggesting separate introductions of A.2.5 in Florida around the same time period, as supported by the MCC phylogeny ( Figure 3 ).

The A.2.5 lineage in Florida became of particular interest due to the presence of mutations in the spike protein, associated with VOCs , including convergent evolution of D614G, a defining mutation A.

B.

C. D.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021. ; among B.1 Pango lineages (31, 32), initially found in clades predominantly in Europe (33, 34). Spike D614G has become the dominant allele in isolates world-wide (34), and has been associated with increased viral loads (32, 34), infections among younger patients (32) and increased entry into human cells (35, 36), suggesting increased infectivity. A.2.5 also contains spike L452R, a CDC-defined SOTC (10), predominantly observed in Epsilon (B.1.427/B.1.429), which emerged in southern California in May 2020 and exhibits 20% increased transmissibility (4) . Allele L452R has independently emerged in several other lineages over the last several months, including Iota (B.1.526), Kappa (B.1.617.1), Delta (B.1.617.2), and C.36 (10) . Spike L452R causes increased infectivity (4) and has been reported to have a 15-fold reduction in susceptibility to combination monoclonal antibody therapy, bamlanivimab together with etesevimab (5) .

Most notable among the Spike mutations in A.2.5 are two novel INDELS, a deletion of positions 141-143 and an insertion of AGY at 215. Both indels are located in the NTD of the spike protein ( Figure  4 ), a site of importance in the host immune response. While the receptor binding domain (RBD) of the S protein has received much of the attention due to the phenotypic impact of ACE2 receptor binding, the NTD has recently emerged as significant in its role as a site for neutralizing antibodies (37-42). Recently, three studies identified an antigenic supersite in the NTD, which includes three of five loops on the NTD at amino acid residues 14-26, 141-156, and 246-260 (39, 40, 42, 43). Notably, the deletion of residues 141-143 in A.2.5 occurs in the NTD antigenic supersite and likely interferes with neutralizing antibody binding, although future studies would need to determine the exact phenotypic effects of this deletion.

Several variants have mutations in the NTD antigenic supersite, suggesting selective pressure on this region by emerging variants to escape NTD-specific neutralizing antibodies (39, 40, 42, 43). Additional mutations causing increased transmissibility are likely key factors in why variants, such as Alpha (B.1.1.7) and Delta (B.1.671.2), have significant case counts around the world and soon became the dominant variant in geographical areas, such as the U.S., India, and the U.K. shortly after they emerged (1, 11, 44, 45) . While A.2.5 does not appear to demonstrate increased transmissibility based on the frequency of the lineage in the U.S. and globally, A.2.5 and its emerging sublineages should continue to be monitored as novel mutations could arise to increase transmissibility.

A.2.5 experienced rapid global expansion early during its emergence, however cases in Florida have been generally low to-date, especially in comparison to other variants (e.g., B.1.1.7, P.1, and B.1.617.2). Lineages with concerning or novel mutations in the NTD or RBD of spike must be further investigated and monitored to determine their phenotypic effects on transmissibility or therapeutics. Case counts and lineage proportions are only one factor when considering the effect of a particular variant on distinct populations within a community. As vaccination rates increase, restrictions continue to lift, and domestic and international travel increase, transmission dynamics will alter, and selective pressures may give rise to additional emerging variants or increase transmission frequencies of currently circulating variants. Continued baseline and targeted surveillance, in addition to contact tracing, are imperative to implement a strong public health response to reduce or eliminate transmission of SC2 concerning variants. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21266538 doi: medRxiv preprint

Detection of a SARS-CoV-2 variant of concern in South Africa

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

2021. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Accessed 2021-06-21. 11. Prevention CfDCa. 2021. Variant Proportions

Tracking SARS-CoV-2 variants

Pango Lineages

Pango Lineages -Lineage A.2

BPHL SARS-CoV-2 Tiled Amplicon Illumina Sequencing

Trimmomatic: a flexible trimmer for Illumina sequence data

Aligning sequence reads, clone sequences and assembly contigs with

Genome Project Data Processing S. 2009. The Sequence Alignment/Map format and SAMtools

An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar

Database resources of the National Center for Biotechnology Information

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Parallelization of MAFFT for large-scale multiple sequence alignments

IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies

TreeTime: Maximum-likelihood phylodynamic analysis

Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. Virus Evolution 4

Posterior Summarization in

Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution

This analysis was funded in part through the Centers for Disease Control and Prevention's Office of Advanced Molecular Detection's support of the Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases Cooperative Agreement. We gratefully acknowledge the authors from the originating and submitting laboratories that provided sequences to GISAID's EpiCoV database that were used in this study as background global samples (Supplemental Table 1